APD developed a single-use device for non-invasive and continuous assessment of microcirculation in critical care and surgical settings. The APD product will detect early signs of sepsis hours, if not days, before the tests currently used and the clinical symptoms. It is based on subtle changes in urethral perfusion. Impairment of local microcirculation during septic shock is a triggering factor for multi-organ dysfunction syndrome and subsequent death. Despite its therapeutic importance, assessment of microcirculation remains difficult, with only non-continuous and deferred measurements when available. After going through pre-clinical validation, First-in-Man clinical trials and receiving CE mark in 2016 for an initial version of the product, APD was acquired by Vygon in 2019.
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.